N/A
Manufactured by Gilead Sciences, Inc.
41,429 FDA adverse event reports analyzed
Last updated: 2026-04-14
SOFOSBUVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Gilead Sciences, Inc.. The most commonly reported adverse reactions for SOFOSBUVIR include FATIGUE, DRUG INEFFECTIVE, HEPATITIS C, HEADACHE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SOFOSBUVIR.
Out of 19,598 classified reports for SOFOSBUVIR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 41,429 FDA FAERS reports that mention SOFOSBUVIR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, DRUG INEFFECTIVE, HEPATITIS C, HEADACHE, NAUSEA, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Gilead Sciences, Inc. in connection with SOFOSBUVIR. Always verify the specific product and NDC with your pharmacist.